Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;26(1):92-101.
doi: 10.1111/resp.13879. Epub 2020 Jun 15.

Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension

Abdullah M Aldalaan  1 , Sarfraz A Saleemi  1 , Ihab Weheba  1 , Abeer Abdelsayed  1 , Maha M Aleid  2 , Fatima Alzubi  1 , Hamdeia Zaytoun  1 , Nadeen Alharbi  1
Affiliations

Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension

Abdullah M Aldalaan et al. Respirology. 2021 Jan.

Abstract

Background and objective: This study presents the first results of 'SAUDIPH' registry, aiming to assess patient characteristics, treatment approach and clinical and survival outcomes in patients with PAH.

Methods: The registry enrolled patients with Group 1 and Group 4 PH under clinical management in a specialized tertiary care centre from 2004 to 2018. Changes from baseline to last follow-up visit were assessed.

Results: A total of 222 patients were enrolled, and Group 1 PH was the most frequent aetiology (57.7%). Mean age at diagnosis was 32 years. mPAP was 55.0 mm Hg and was higher for Group 1 PH (59.0 mm Hg, P < 0.001). At the last visit, most patients were on specific therapy (83.7%) and 30% shifted from FC III/IV to FC I/II. NT-proBNP improved by 29.2% in the overall population. The 1-, 3- and 5-year cumulative probabilities of survival were 95.6% (95% CI: 91.5-99.9%), 89.2% (95% CI: 82.1-96.9%) and 74.6% (95% CI: 59.4-93.7%), respectively. CHD-PAH demonstrated the best survival among Group 1 PAH with 1-, 3- and 5-year cumulative probability of 100%, 100%, and 75.0% (95% CI: 42.6-100), respectively.

Conclusion: PAH was the most frequent aetiology and patients were younger at diagnosis compared to other cohorts. Most patients showed improvement in FC and NT-proBNP. The estimated 1-year survival was better than previous studies, possibly reflecting wider use of combination therapy and the high prevalence of CHD-PAH.

Keywords: pulmonary arterial hypertension; pulmonary hypertension; real-world data; registry; survival.

PubMed Disclaimer

References

REFERENCES

    1. Hemnes AR, Humbert M. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. Eur. Respir. Rev. 2017; 26: 170093.
    1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019; 53: 1801913.
    1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009; 54: S43-54.
    1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2013; 62: D34-41.
    1. Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases 2018; 6: 38.

Substances

LinkOut - more resources